SCHEMBL2662014

SCHEMBL2662014

O=c1[nH]cccc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2101505 0.72 AURKA (0.56)
SCHEMBL2645298 0.70
SCHEMBL1422273 0.70
SCHEMBL30033470 0.70 PARP1 (0.60)
SCHEMBL1536658 0.70 PARP1 (0.60)
SCHEMBL30106473 0.69 PDGFRB (0.42)
SCHEMBL908781 0.69 KDM4E (0.47)
SCHEMBL10587082 0.69 DAO (0.46)
SCHEMBL7834765 0.68
SCHEMBL4073763 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117396074-A Fungicidal compositions containing oxadiazole compounds PI工业有限公司 2024-01-12 CN claimed
CN-113207884-B Application of fluazinone as strigolactone inhibitor 湖南农业大学 2022-06-21 CN claimed
CN-113243372-A Application of fluazinone in promotion of rice shoot differentiation and ratoon rice planting 湖南农业大学 2021-08-13 CN claimed
CN-113207884-A Application of fluazinone as strigolactone inhibitor 湖南农业大学 2021-08-06 CN claimed
EP-4741390-A1 BIARYL RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd. (CN) 2026-05-13 EP disclosed
US-20260060975-A1 INHIBITING MUTANT IDH-1 FORMA THERAPEUTICS, INC. (US) 2026-03-05 US disclosed
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE GILEAD SCIENCES, INC. 2026-01-22 US disclosed
US-20260014138-A1 INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) FORMA THERAPEUTICS, INC. (US) 2026-01-15 US disclosed
US-20260000664-A1 TREATING PATIENTS HARBORING AN ISOCITRATE DEHYDROGENASE-1 (IDH-1) MUTATION FORMA THERAPEUTICS, INC. (US) 2026-01-01 US disclosed
EP-4594316-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE Repare Therapeutics Inc. (CA) 2025-08-06 EP disclosed
CN-120225504-A Fluorine-containing pyridone compound and process for producing the same 优迈特株式会社 2025-06-27 CN disclosed
WO-2025067126-A1 PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION 深圳信立泰药业股份有限公司 2025-04-03 WO disclosed
CN-103443079-A Fluoropyridone derivatives useful as antibacterial agents PFIZER 2013-12-11 CN disclosed
WO-2011075602-A1 METHODS OF PREPARING FACTOR XA INHIBITORS AND SALTS THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-06-23 WO disclosed
EP-1907387-A1 AN OXIME DERIVATIVE AND PREPARATIONS THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2008-04-09 EP disclosed
WO-2007007886-A1 AN OXIME DERIVATIVE AND PREPARATIONS THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-18 WO disclosed
EP-1163194-A1 SELECTIVE NITROGEN FUNCTIONALISATION OF ORGANIC COMPOUNDS F2 Chemicals Limited (GB) 2001-12-19 EP disclosed
WO-2001053234-A1 SELECTIVE NITROGEN FUNCTIONALISATION OF ORGANIC COMPOUNDS F2 CHEMICALS LIMITED (GB) 2001-07-26 WO disclosed
WO-1992012983-A1 A METHOD OF FLUORINATING BY USING N-FLUOROPYRIDINIUM PYRIDINE HEPTAFLUORODIBORATE ALLIED-SIGNAL INC. (US) 1992-08-06 WO disclosed
US-4008086-A PYRIDONE OR PYRIDAZONE DERIVATIVES KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) 1977-02-15 US disclosed